Oncolytics Biotech (NASDAQ:ONCY) Upgraded to “Moderate Buy” at Raymond James

Raymond James upgraded shares of Oncolytics Biotech (NASDAQ:ONCY) to a moderate buy rating in a research report released on Thursday morning,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

Several other analysts have also issued reports on the stock. Leede Financial lowered shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Oncolytics Biotech in a research note on Thursday.

Oncolytics Biotech Trading Down 3.0 %

Shares of NASDAQ:ONCY traded down $0.03 on Thursday, hitting $0.98. 245,358 shares of the company were exchanged, compared to its average volume of 328,224. The stock’s 50 day moving average price is $1.09 and its 200 day moving average price is $1.06. The firm has a market capitalization of $75.53 million, a P/E ratio of -3.63 and a beta of 1.69. Oncolytics Biotech has a 1-year low of $0.84 and a 1-year high of $1.75.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC bought a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech as of its most recent SEC filing. 6.82% of the stock is currently owned by institutional investors.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.